Chinook Therapeutics

Chinook Therapeutics

Edit info

  • Founded: 2019
  • Location: Vancouver , BC
  • Employee range: 50 - 200
  • Clinical stage: Clin3
  • Therapy area: IgA nephropathy
  • Drug types: NPH, RAR
  • Lead product: Atrasentan
  • Funding: $106M stock Aug 2020; $65M A Aug 2019
  • Investors: Versant


chinooktx.com

linkedin.com

job board


Drug notes:

Also Clin2 glomerular diseases; BION-1301 Clin2 IgA nephropathy; CHK-336 Clin1 primary hyperoxaluria; undisclosed programs RD/Clin0 rare kidney diseases

About:

Chinook Therapeutics is developing precision medicines for rare, severe chronic kidney diseases. Chronic kidney diseases are a growing worldwide problem with ineffective treatments and often lead to high medical costs, dialysis or transplantation. Chinook is capitalizing on the new understanding of kidney disease biology to discover and develop new precision medicines. For example, Chinook’s lead candidate, atrasentan, targets and blocks the endothelin A receptor and is currently being tested in a phase 3 clinical trial. By further exploring the latest biological insights from single cell RNA sequencing of patient kidney samples, Chinook seeks to build their therapeutic pipeline to target more kidney disease pathways.

Jobs:

Post a job


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com